Valeria Magarotto

Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe

Valeria Magarotto, Julien Thévenon, Kate Morgan, Silène Ten Seldam et autres

Purpose: To provide real-world data on patient perceptions and experiences with subcutaneous (SC) versus intravenous (IV) daratumumab. Patients and Methods: This was a cross-sectional, mixed-method (qualitative/quantitative) survey conducted in France, Germany, Spain and the United Kingdom involving multiple myeloma (MM) patients who …

it, fr, be, us (code pays fourni par la source)

RWD56 Expert Consensus on Diagnosis, Risk Stratification, and Treatment of Smoldering Multiple Myeloma: Results From a Multinational Delphi Panel Study

Judi Brown, B Cieply, K. Matt, Gros Otero B et autres

us, gb, de, it (code pays fourni par la source)

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

Arnaud Jaccard, Frank Bridoux, Wilfried W. H. Roeloffzen, Monique C. Minnema et autres

fr, nl, pt, cz, es, it, de, gr, gb, at (code pays fourni par la source)

PB2679: MIXED-METHOD, CROSS-SECTIONAL SURVEY TO DESCRIBE FEELINGS, PERCEPTION, AND EXPERIENCE OF MULTIPLE MYELOMA PATIENTS WHO SWITCHED FROM INTRAVENOUS DARATUMUMAB TO THE SUBCUTANEOUS FORMULATION IN EUROPE

Valeria Magarotto, Julien Thévenon, Kate Morgan, Silène Ten Seldam et autres

Topic: 35. Quality of life and palliative care Background: Multiple myeloma (MM) is the second most prevalent haematological malignancy. MM incidence increases with age, and its symptom burden varies from physical impairment such as pain, anaemia, bone lesions, and renal dysfunction to …

it, fr, be, de (code pays fourni par la source)

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results from the Real-World, Retrospective EMN23 Study

Arnaud Jaccard, Frank Bridoux, Wilfried W. H. Roeloffzen, Monique C. Minnema et autres

us, fr, nl, pt, cz, es, it, de, gr, gb, at, be, il (code pays fourni par la source)

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Stefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, Attilio Guarini et autres

Abstract Introduction Ibrutinib is the only once-daily Bruton's tyrosine kinase (BTK) inhibitor with significant survival benefit vs chemo- and /or immunotherapy in multiple phase 3 studies of patients (pts) with chronic lymphocytic leukemia (CLL). It has profoundly changed the treatment landscape of …

it (code pays fourni par la source)

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

Sally A. Hunsucker, Deborah J. Kuhn, Robert Z. Orlowski, Valeria Magarotto et autres

Signalling through the interleukin (IL)-6 pathway induces proliferation and drug resistance of multiple myeloma cells. We therefore sought to determine whether the IL-6-neutralizing monoclonal antibody siltuximab, formerly CNTO 328, could enhance the activity of melphalan, and to examine some of the mechanisms …

us (code pays fourni par la source)

Lenalidomide and low‐dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials

Massimo Gentile, Valeria Magarotto, Massimo Offidani, Pellegrino Musto et autres

There are currently no direct head-to-head clinical trials evaluating bortezomib-melphalan-prednisone (VMP) versus lenalidomide and low-dose dexamethasone (Rd). VMP (257 cases) and Rd (222 cases) arms of two randomized phase III trials were employed to assess the treatment influence on outcome in untreated …

it (code pays fourni par la source)

A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients

Sara Bringhen, Valeria Magarotto, Anna Marina Liberati, Angelo Belotti et autres

Abstract Background: Survival rates of multiple myeloma (MM) patients (pts) has improved over the past few years, but patients inevitably relapse and become more resistant to subsequent treatments. Carfilzomib and Pomalidomide were both approved for the treatment of relapsed/refractory MM (RRMM). Combinations …

it, nl (code pays fourni par la source)

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).

Michel Attal, Antonio Pierangelo Palumbo, Sarah A. Holstein, Valérie Lauwers‐Cancès et autres

8001 Background: Several studies demonstrate that LEN MNTC post ASCT reduces the risk of disease progression or death in patients (pts) with MM by ≈ 50% (Attal NEJM 2012; McCarthy NEJM 2012; Palumbo NEJM 2014). However, these studies were not powered for …

fr, it, us (code pays fourni par la source)

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar et autres

fr, ch, gb, it (code pays fourni par la source)

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Valeria Magarotto, Sara Bringhen, Massimo Offidani, Giulia Benevolo et autres

Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus low-dose dexamethasone (Rd). The primary end point was …

it, cz (code pays fourni par la source)